Literature DB >> 8402611

Dominant negative effect of a germ-line mutant p53: a step fostering tumorigenesis.

S Srivastava1, S Wang, Y A Tong, Z M Hao, E H Chang.   

Abstract

Lysates derived from the fibroblasts of individuals who are homozygous for normal p53 or heterozygous for the germ-line p53 mutation characteristic of certain Li-Fraumeni cancer-prone families were assessed for p53 function utilizing the binding of p53 protein to a p53-specific consensus oligonucleotide sequence. As expected, control nuclear lysates containing only mutant p53 or no p53 displayed little or no such binding. However, the nuclear lysates from heterozygous fibroblasts containing similar amounts of normal p53 and 245D mutant p53 displayed binding that was significantly below 50% of that seen with homozygous wild-type p53 in normal cell lysates. The nuclear lysates of these heterozygous or homozygous fibroblasts exhibited similar levels of DNA binding to a consensus oligonucleotide specific for the transcription factor, AP-1. These results indicate that mutant p53 has a transdominant effect on the binding of DNA by normal p53. These findings also suggest that p53 complexes formed in vivo that contain mutant p53 are functionally impaired even if normal p53 is also present in the complex. The implications of a trans-dominant effect of mutant p53 on the cancer-prone phenotype of individuals heterozygous for mutated p53 in Li-Fraumeni families is discussed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8402611

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis.

Authors:  D Matas; A Sigal; P Stambolsky; M Milyavsky; L Weisz; D Schwartz; N Goldfinger; V Rotter
Journal:  EMBO J       Date:  2001-08-01       Impact factor: 11.598

2.  Inhibition of stress-inducible kinase pathways by tumorigenic mutant p53.

Authors:  Yoichi Ohiro; Anny Usheva; Shinichiro Kobayashi; Shannon L Duffy; Regan Nantz; David Gius; Nobuo Horikoshi
Journal:  Mol Cell Biol       Date:  2003-01       Impact factor: 4.272

Review 3.  Stage-specific gene expression during hepatocarcinogenesis in the rat.

Authors:  H C Pitot
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

4.  A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies.

Authors:  Steffen Boettcher; Peter G Miller; Rohan Sharma; Marie McConkey; Matthew Leventhal; Andrei V Krivtsov; Andrew O Giacomelli; Waihay Wong; Jesi Kim; Sherry Chao; Kari J Kurppa; Xiaoping Yang; Kirsten Milenkowic; Federica Piccioni; David E Root; Frank G Rücker; Yael Flamand; Donna Neuberg; R Coleman Lindsley; Pasi A Jänne; William C Hahn; Tyler Jacks; Hartmut Döhner; Scott A Armstrong; Benjamin L Ebert
Journal:  Science       Date:  2019-08-09       Impact factor: 47.728

Review 5.  Chromosome instability and deregulated proliferation: an unavoidable duo.

Authors:  Courtney H Coschi; Frederick A Dick
Journal:  Cell Mol Life Sci       Date:  2012-01-06       Impact factor: 9.261

Review 6.  Cell cycle control, checkpoint mechanisms, and genotoxic stress.

Authors:  R E Shackelford; W K Kaufmann; R S Paules
Journal:  Environ Health Perspect       Date:  1999-02       Impact factor: 9.031

Review 7.  Comparative Aspects of Osteosarcoma Pathogenesis in Humans and Dogs.

Authors:  Timothy M Fan; Chand Khanna
Journal:  Vet Sci       Date:  2015-08-17

8.  Gene Prioritization through Consensus Strategy, Enrichment Methodologies Analysis, and Networking for Osteosarcoma Pathogenesis.

Authors:  Alejandro Cabrera-Andrade; Andrés López-Cortés; Gabriela Jaramillo-Koupermann; César Paz-Y-Miño; Yunierkis Pérez-Castillo; Cristian R Munteanu; Humbert González-Díaz; Alejandro Pazos; Eduardo Tejera
Journal:  Int J Mol Sci       Date:  2020-02-05       Impact factor: 5.923

9.  Abnormal pattern of post-gamma-ray DNA replication in radioresistant fibroblast strains from affected members of a cancer-prone family with Li-Fraumeni syndrome.

Authors:  R Mirzayans; R A Aubin; W Bosnich; W A Blattner; M C Paterson
Journal:  Br J Cancer       Date:  1995-06       Impact factor: 7.640

10.  Re-engineered p53 chimera with enhanced homo-oligomerization that maintains tumor suppressor activity.

Authors:  Abood Okal; Sean Cornillie; Stephan J Matissek; Karina J Matissek; Thomas E Cheatham; Carol S Lim
Journal:  Mol Pharm       Date:  2014-05-29       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.